Alemtuzumab (Campath-1H) therapy for refractory rejections in pediatric heart transplant recipients

Bibhuti Das, Vivian Dimas, Kristine Guleserian, Chantale Lacelle, Kristin Anton, Lindy Moore, Robert Morrow

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Despite substantial improvements in survival after pediatric heart transplantation, refractory rejection remains a major cause of morbidity and mortality. We have utilized ALE (Campath-1H) in six consecutive patients with refractory rejection. These rejection episodes persisted despite conventional treatment, which included intravenous methylprednisolone, rituximab, immunoglobulin G, and antithymocyte globulin. In our series, after ALE therapy, LV SF increased from 22%±5% to 33%±5% (P=.01). However, in our series, ALE therapy neither led to persistent LV function recovery nor could it prevent subsequent antibody-mediated rejection.

Original languageEnglish (US)
Article numbere12844
JournalPediatric Transplantation
Volume21
Issue number1
DOIs
StatePublished - Feb 1 2017

Keywords

  • alemtuzumab (Campath-1H)
  • pediatric heart transplant
  • refractory acute rejections

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Fingerprint Dive into the research topics of 'Alemtuzumab (Campath-1H) therapy for refractory rejections in pediatric heart transplant recipients'. Together they form a unique fingerprint.

Cite this